申请人:Taisho Pharmaceutical Co., Ltd.
公开号:EP2604602A1
公开(公告)日:2013-06-19
A compound represented by formula [I] and a pharmaceutically accepted salt of said compound are a novel compound and a phamaceutically accepted salt thereof which exert antagonistic activity against group II metabotropic glutamate (mGlu) receptors, and are effective as a novel preventive or therapeutic agent for disorders such as mood disorders (depressive disorder, bipolar disorder, etc.), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, a specific phobic disorder, acute stress disorder, etc.), schizophrenia, Alzheimer's disease, cognitive impairment, dementia, drug dependence, convulsions, shivering, pain, sleep disorders, and the like.
一种由式[I]代表的化合物及其药学上可接受的盐是一种新型化合物及其药学上可接受的盐,它们对 II 组代谢谷
氨酸(mGlu)受体具有拮抗活性,可作为新型预防或治疗剂有效地治疗各种疾病,如情绪障碍(抑郁障碍、双相情感障碍等)、焦虑障碍(广泛性焦虑障碍、惊恐障碍、强迫症、社交焦虑障碍、创伤后应激障碍、特定恐惧症、急性应激障碍等)、精神分裂症、焦虑症等。焦虑症(广泛性焦虑症、恐慌症、强迫症、社交焦虑症、创伤后应激障碍、特定恐惧症、急性应激障碍等)、精神分裂症、阿尔茨海默病、认知障碍、痴呆症、药物依赖、抽搐、颤抖、疼痛、睡眠障碍等。